Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.
Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.
Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.
Exact Sciences (NASDAQ: EXAS) announced advancements in cancer detection at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The company emphasizes the efficiency of advanced imaging after a positive multi-cancer early detection (MCED) test for identifying tumor locations. Preliminary findings suggest potential for molecular residual disease (MRD) detection technologies in monitoring cancer recurrence post-therapy. Key presentations include data showing fewer diagnostic procedures needed with advanced imaging compared to molecular testing, and promising results from tumor-informed MRD methodologies in distinguishing cancer samples. The developments could enhance early detection strategies and improve treatment decision-making for patients.
Exact Sciences Corp. (NASDAQ: EXAS) announced it will release its Q1 2023 financial results on May 9, 2023, after U.S. financial markets close. A conference call and webcast will follow at 5 p.m. ET to discuss the results and business developments. Exact Sciences, a leader in cancer screening and diagnostics, is known for its innovative products like Cologuard® and Oncotype®. The company continues to invest in its product pipeline to enhance patient care before and during cancer treatment.
For details, join the webcast at www.exactsciences.com or dial in at 888-330-2384 (domestic) and +1 240-789-2701 (international).
Exact Sciences Corp. (Nasdaq: EXAS) announced a transaction on February 23, 2023, involving the exchange of $500 million in new 2.00% Convertible Senior Notes due March 1, 2030, for existing convertible notes totaling approximately $384 million and $138 million in cash. The transaction is set to close on March 1, 2023. The new notes will have a semi-annual interest payment structure and can be converted into shares of common stock or cash, beginning September 1, 2023. The initial conversion price is about $80.83 per share, indicating a 25% premium over the previous closing price of $64.66.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
